Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
Other Long-Term Assets
Zealand Pharma A/S
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Other Long-Term Assets
kr985k
|
CAGR 3-Years
-72%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-10%
|
|
|
Genmab A/S
CSE:GMAB
|
Other Long-Term Assets
kr908m
|
CAGR 3-Years
51%
|
CAGR 5-Years
46%
|
CAGR 10-Years
65%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Other Long-Term Assets
kr45.5m
|
CAGR 3-Years
2%
|
CAGR 5-Years
99%
|
CAGR 10-Years
-9%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Saniona AB
STO:SANION
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zealand Pharma A/S
Glance View
Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.
See Also
What is Zealand Pharma A/S's Other Long-Term Assets?
Other Long-Term Assets
985k
DKK
Based on the financial report for Dec 31, 2024, Zealand Pharma A/S's Other Long-Term Assets amounts to 985k DKK.
What is Zealand Pharma A/S's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
-10%
Over the last year, the Other Long-Term Assets growth was 6%. The average annual Other Long-Term Assets growth rates for Zealand Pharma A/S have been -72% over the past three years , -36% over the past five years , and -10% over the past ten years .
You don't have any saved screeners yet